Cargando…
Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review
The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrine tumors (NETs) of the GastroEnteroPancreatic-(GEP-) system depending on tumor primary location and meta...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712684/ https://www.ncbi.nlm.nih.gov/pubmed/24213232 http://dx.doi.org/10.3390/cancers4010141 |
_version_ | 1782277099305828352 |
---|---|
author | Nölting, Svenja Kuttner, Axel Lauseker, Michael Vogeser, Michael Haug, Alexander Herrmann, Karin A. Hoffmann, Johannes N. Spitzweg, Christine Göke, Burkhard Auernhammer, Christoph J. |
author_facet | Nölting, Svenja Kuttner, Axel Lauseker, Michael Vogeser, Michael Haug, Alexander Herrmann, Karin A. Hoffmann, Johannes N. Spitzweg, Christine Göke, Burkhard Auernhammer, Christoph J. |
author_sort | Nölting, Svenja |
collection | PubMed |
description | The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrine tumors (NETs) of the GastroEnteroPancreatic-(GEP-) system depending on tumor primary location and metastatic spread. In a retrospective single-center series, sensitivities were evaluated in serum samples from 110 patients with midgut (n = 62) and pancreatic (n = 48) NETs. CgA levels were analyzed by a commercially-available immunoradiometric assay (CIS-bio) during routine follow-up in the years 2000–2009. CgA showed a higher sensitivity for midgut (68%) than pancreatic (54%) NETs. A higher CgA sensitivity and significantly higher median CgA values were found in patients with liver metastases than in those without, and in patients with hepatic and additionally extra-hepatic metastases than in those with hepatic and nodal metastases alone, respectively. We found an overall sensitivity for elevated 5HIAA excretion of 69% for midgut NETs and a significant correlation between median CgA and 5-HIAA values. The sensitivity of AP and the correlations of AP/CgA-data-pairs were low in both midgut and pancreatic NETs, although highest for metastatic pancreatic NETs. The sensitivity of CgA measurement depends on the NET primary location and spread of disease. 5-HIAA and CgA showed comparable sensitivity in midgut NETs, while AP does not seem to be useful as a tumor marker in GEP-NETs. |
format | Online Article Text |
id | pubmed-3712684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-37126842013-08-05 Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review Nölting, Svenja Kuttner, Axel Lauseker, Michael Vogeser, Michael Haug, Alexander Herrmann, Karin A. Hoffmann, Johannes N. Spitzweg, Christine Göke, Burkhard Auernhammer, Christoph J. Cancers (Basel) Article The aim of this study was to assess the clinical sensitivities of the tumor markers chromogranin A (CgA), urinary 5-hydroxyindoleacetic acid (5-HIAA) and alkaline phosphatase (AP) in neuroendocrine tumors (NETs) of the GastroEnteroPancreatic-(GEP-) system depending on tumor primary location and metastatic spread. In a retrospective single-center series, sensitivities were evaluated in serum samples from 110 patients with midgut (n = 62) and pancreatic (n = 48) NETs. CgA levels were analyzed by a commercially-available immunoradiometric assay (CIS-bio) during routine follow-up in the years 2000–2009. CgA showed a higher sensitivity for midgut (68%) than pancreatic (54%) NETs. A higher CgA sensitivity and significantly higher median CgA values were found in patients with liver metastases than in those without, and in patients with hepatic and additionally extra-hepatic metastases than in those with hepatic and nodal metastases alone, respectively. We found an overall sensitivity for elevated 5HIAA excretion of 69% for midgut NETs and a significant correlation between median CgA and 5-HIAA values. The sensitivity of AP and the correlations of AP/CgA-data-pairs were low in both midgut and pancreatic NETs, although highest for metastatic pancreatic NETs. The sensitivity of CgA measurement depends on the NET primary location and spread of disease. 5-HIAA and CgA showed comparable sensitivity in midgut NETs, while AP does not seem to be useful as a tumor marker in GEP-NETs. MDPI 2012-02-15 /pmc/articles/PMC3712684/ /pubmed/24213232 http://dx.doi.org/10.3390/cancers4010141 Text en © 2012 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Nölting, Svenja Kuttner, Axel Lauseker, Michael Vogeser, Michael Haug, Alexander Herrmann, Karin A. Hoffmann, Johannes N. Spitzweg, Christine Göke, Burkhard Auernhammer, Christoph J. Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review |
title | Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review |
title_full | Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review |
title_fullStr | Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review |
title_full_unstemmed | Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review |
title_short | Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review |
title_sort | chromogranin a as serum marker for gastroenteropancreatic neuroendocrine tumors: a single center experience and literature review |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712684/ https://www.ncbi.nlm.nih.gov/pubmed/24213232 http://dx.doi.org/10.3390/cancers4010141 |
work_keys_str_mv | AT noltingsvenja chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT kuttneraxel chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT lausekermichael chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT vogesermichael chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT haugalexander chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT herrmannkarina chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT hoffmannjohannesn chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT spitzwegchristine chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT gokeburkhard chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview AT auernhammerchristophj chromograninaasserummarkerforgastroenteropancreaticneuroendocrinetumorsasinglecenterexperienceandliteraturereview |